Sclerostin and dickkopf-1 in renal osteodystrophy

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 4, 2011, Pages 877-882

  Cejka, Daniel ^a   Herberth, Johann ^b   Branscum, Adam J ^b   Fardo, David W ^b   Monier Faugere, Marie Claude ^b   Diarra, Danielle ^a   Haas, Martin ^a   Malluche, Hartmut H ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; DICKKOPF 1 PROTEIN; PARATHYROID HORMONE; PHOSPHORUS; SCLEROSTIN;

ADULT; AGED; ARTICLE; BONE BIOPSY; BONE DENSITY; BONE MINERALIZATION; BONE TURNOVER; CELL COUNT; CELL FUNCTION; CHRONIC KIDNEY DISEASE; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DIALYSIS; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORPHOMETRICS; OSTEOBLAST; PARATHYROID HORMONE BLOOD LEVEL; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; RENAL OSTEODYSTROPHY;

ADULT; AGED; BONE MORPHOGENETIC PROTEINS; BONE REMODELING; BONE RESORPTION; CALCIFICATION, PHYSIOLOGIC; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; GENETIC MARKERS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY DISEASES; MALE; MIDDLE AGED; OSTEOGENESIS; PARATHYROID HORMONE; RENAL OSTEODYSTROPHY;

EID: 79955552110     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.06550810     Document Type: Article

References (34)

1. Malluche H, Faugere MC: Renal bone disease 1990: An unmet challenge for the nephrologist. Kidney Int 38: 193-211, 1990
2. Malluche HH, Koszewski N, Monier-Faugere MC, Williams JP, Mawad H: Influence of the parathyroid glands on bone metabolism. Eur J Clin Invest 36[Suppl 2]: 23-33, 2006
3. Baron R, Rawadi G: Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 148: 2635-2643, 2007
4. Krishnan V, Bryant HU, Macdougald OA: Regulation of bone mass by Wnt signaling. J Clin Invest 116: 1202-1209, 2006
5. Veverka V, Henry AJ, Slocombe PM, Ventom A, Mulloy B, Muskett FW, Muzylak M, Greenslade K, Moore A, Zhang L, Gong J, Qian X, Paszty C, Taylor RJ, Robinson MK, Carr MD: Characterization of the structural features and interactions of sclerostin: Molecular insight into a key regulator of Wnt-me-diated bone formation. J Biol Chem 284: 10890-10900, 2009
6. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA: Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22: 6267-6276, 2003
7. Kusu N, Laurikkala J, Imanishi M, Usui H, Konishi M, Miyake A, Thesleff I, Itoh N: Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. J Biol Chem 278: 24113-24117, 2003
8. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Ko-stenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C: Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 23: 860-869, 2008
9. Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dio-szegi M, Lacza C, Wuyts W, Van Den Ende J, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dik-kers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van Hul W: Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10: 537-543, 2001
10. Balemans W, Patel N, Ebeling M, Van Hul E, Wuyts W, Lacza C, Dioszegi M, Dikkers FG, Hildering P, Willems PJ, Verheij JB, Lindpaintner K, Vickery B, Foernzler D, Van Hul W: Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 39: 91-97, 2002
11. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Si-monet WS, Lacey DL, Paszty C: Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24: 578-588, 2009
12. Ominsky MS, Vlasseros F, Jolette J, Smith SY, Stouch B, Doellgast G, Gong J, Gao Y, Cao J, Graham K, Tipton B, Cai J, Deshpande R, Zhou L, Hale MD, Lightwood DJ, Henry AJ, Popplewell AG, Moore AR, Robinson MK, Lacey DL, Simonet WS, Paszty C: Two doses of sclerostin antibody in cynomol-gus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 25: 948-959, 2010
13. Padhi D, Stouch B, Jang G, Fang L, Darling M, Glise H, Robinson M, Harris S, Posvar E: Anti-sclerostin antibody increases markers of bone formation in healthy postmenopausal women [abstract]. J Bone Miner Metab 22[Suppl 1]: 37, 2007
14. Pinzone JJ, Hall BM, Thudi NK, Vonau M, Qiang YW, Rosol TJ, Shaughnessy JD Jr.: The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood 113: 517-525, 2009
15. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD Jr.: The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349: 2483-2494, 2003
16. Morvan F, Boulukos K, Clement-Lacroix P, Roman Roman S, Suc-Royer I, Vayssiere B, Ammann P, Martin P, Pinho S, Po-gnonec P, Mollat P, Niehrs C, Baron R, Rawadi G: Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res 21: 934-945, 2006
17. Fulciniti M, Tassone P, Hideshima T, Vallet S, Nanjappa P, Ettenberg SA, Shen Z, Patel N, Tai YT, Chauhan D, Mitsiades C, Prabhala R, Raje N, Anderson KC, Stover DR, Munshi NC: Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 114: 371-379, 2009
18. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O'Brien CA, Manolagas SC, Jilka RL: Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by os-teocytes: A novel mechanism for hormonal control of os-teoblastogenesis. Endocrinology 146: 4577-4583, 2005
19. Keller H, Kneissel M: SOST is a target gene for PTH in bone. Bone 37: 148-158, 2005
20. Kulkarni NH, Halladay DL, Miles RR, Gilbert LM, Frolik CA, Galvin RJ, Martin TJ, Gillespie MT, Onyia JE: Effects of parathyroid hormone on Wnt signaling pathway in bone. J Cell Biochem 95: 1178-1190, 2005
21. O'Brien CA, Plotkin LI, Galli C, Goellner JJ, Gortazar AR, Allen MR, Robling AG, Bouxsein M, Schipani E, Turner CH, Jilka RL, Weinstein RS, Manolagas SC, Bellido T: Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One 3: e2942, 2008
22. Malluche HH, Faugere MC: Atlas of Mineralized Bone Histology, New York, Karger, 1986
23. Goldner J: A modification of the Masson trichrome technique for routine laboratory purposes. Am J Pathol 14: 237-243, 1938
24. Lillie PD, Fullmer HM: Histopathologic Technique and Practical Histochemistry, New York, McGraw Hill, 1976
25. Denton J, Freemont AJ, Ball J: Detection of distribution of aluminum in bone. J Clin Pathol 37: 136-142, 1984
26. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche HH, Meunier PJ, Ott SM, Recker RR: Bone histomorphom-etry: standardization of nomenclature, symbols and units. J Bone Miner Res 6: 595-610, 1987
27. Sawaya BP, Butros R, Naqvi S, Geng Z, Mawad H, Friedler R, Fanti P, Monier-Faugere MC, Malluche HH: Differences in bone turnover and intact PTH levels between African American and Caucasian patients with end-stage renal disease. Kidney Int 64: 737-742, 2003
28. Malluche HH, Monier-Faugere MC, Wang G, Fraza OJ, Char-ytan C, Coburn JW, Coyne DW, Kaplan MR, Baker N, Mc-Cary LC, Turner SA, Goodman WG: An assessment of cina-calcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Nephrol 69: 269-278, 2008
29. Ferreira A, Frazao JM, Monier-Faugere MC, Gil C, Galvao J, Oliveira C, Baldaia J, Rodrigues I, Santos C, Ribeiro S, Hoenger RM, Duggal A, Malluche HH: Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystro-phy in hemodialysis patients. J Am Soc Nephrol 19: 405-412, 2008
30. Mirza FS, Padhi ID, Raisz LG, Lorenzo JA: Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab 95: 1991-1997, 2010
31. Guo J, Liu M, Yang D, Bouxsein ML, Saito H, Galvin RJ, Kuhstoss SA, Thomas CC, Schipani E, Baron R, Bringhurst FR, Kronenberg HM: Suppression of Wnt signaling by Dkk1 attenuates PTH-mediated stromal cell response and new bone formation. Cell Metab 11: 161-171, 2010
32. Anastasilakis AD, Polyzos SA, Avramidis A, Toulis KA, Pa-patheodorou A, Terpos E: The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis. Clin Endocrinol (Oxf) 72: 752-757, 2010
33. Reppe S, Refvem H, Gautvik VT, Olstad OK, Hovring PI, Re-inholt FP, Holden M, Frigessi A, Jemtland R, Gautvik KM: Eight genes are highly associated with BMD variation in post-menopausal Caucasian women. Bone 46: 604-612, 2010
34. Garnero P, Tabassi NC, Voorzanger-Rousselot N: Circulating dickkopf-1 and radiological progression in patients with early rheumatoid arthritis treated with etanercept. J Rheumatol 35: 2313-2315, 2008